[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [
      "Your Experience in the Past Year"
    ],
    "rows": [
      [
        "1.",
        "Alcohol is often taken in larger amounts or over a longer period than intended.",
        "The presence of at least 2 of these symptoms indicates an AUD:Mild:2‐3 symptomsModerate:4‐5 symptomsSevere:6 or more symptoms"
      ],
      [
        "2.",
        "There is a persistent desire or unsuccessful efforts to cut down or control alcohol use."
      ],
      [
        "3.",
        "A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects."
      ],
      [
        "4.",
        "Craving, or a strong desire or urge to use alcohol."
      ],
      [
        "5.",
        "Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, school, or home."
      ],
      [
        "6.",
        "Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of alcohol."
      ],
      [
        "7.",
        "Important social, occupational, or recreational activities are given up or reduced because of alcohol use."
      ],
      [
        "8.",
        "Recurrent alcohol use in situations in which it is physically hazardous."
      ],
      [
        "9.",
        "Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol."
      ],
      [
        "10.",
        "Tolerance, defined as either of the following:Need for markedly increased amounts of alcohol to achieve intoxication or desired effect; orMarkedly diminished effect with continued use of the same amount of alcohol."
      ],
      [
        "11.",
        "Withdrawal, as manifested by either of the following:The characteristic alcohol withdrawal syndrome; orAlcohol (or a closely related substance, such as a benzodiazepine) is taken to relieve or avoid withdrawal symptoms."
      ]
    ],
    "row_count": 11,
    "column_count": 1
  },
  {
    "table_index": 3,
    "headers": [
      "Test",
      "Source",
      "Detection Time",
      "Cutoff Values",
      "Sensitivity",
      "Specificity",
      "PPV",
      "NPV",
      "Clinical Use"
    ],
    "rows": [
      [
        "CDT/%CDT*",
        "Blood",
        "2‐3 weeks",
        "1.7%‐2.6%",
        "21%‐50%",
        "50%‐100%",
        "64%‐100%",
        "86%‐93%",
        "Lower sensitivity and specificity"
      ],
      [
        "EtG",
        "Urine",
        "3 days",
        "500 ng/mL",
        "76%‐89%",
        "93%‐99%",
        "81%‐90%",
        "91%‐99%",
        "False positives and greater patient awareness of testing"
      ],
      [
        "EtG",
        "Hair",
        "Months",
        "30 pg/mg",
        "81%‐100%",
        "83%‐98%",
        "68%‐95%",
        "86%‐100%",
        "Costly, requires significant hair sample, limited availability"
      ],
      [
        "EtS",
        "Urine",
        "3 days",
        "75 ng/mL",
        "82%",
        "86%",
        "70%",
        "93%",
        "Often used to confirm + EtG"
      ],
      [
        "PEth",
        "Blood",
        "2‐3 weeks",
        "20 ng/mL",
        "97%‐100%",
        "66%‐96%",
        "85%",
        "100%",
        "More costly than urine EtG"
      ]
    ],
    "row_count": 5,
    "column_count": 9
  },
  {
    "table_index": 4,
    "headers": [
      "",
      "Sensitivity",
      "Specificity",
      "PPV",
      "NPV"
    ],
    "rows": [
      [
        "Andresen‐Streichert42"
      ],
      [
        "%CDT",
        "21% (6‐45)",
        "100% (96‐100)",
        "100% (39‐100)",
        "—"
      ],
      [
        "Urine EtG",
        "71% (41‐91)",
        "98% (94‐100)",
        "90% (58‐99)",
        "95% (89‐98)"
      ],
      [
        "Hair EtG",
        "84% (54‐98)",
        "92% (82‐97)",
        "68% (41‐89)",
        "96% (88‐99)"
      ],
      [
        "PEth",
        "100% (79‐100)",
        "96% (91‐99)",
        "85% (62‐96)",
        "100% (96‐100)"
      ],
      [
        "Staufer43"
      ],
      [
        "%CDT",
        "25%",
        "98%",
        "64%",
        "93%"
      ],
      [
        "Urine EtG",
        "89%",
        "99%",
        "89%",
        "99%"
      ]
    ],
    "row_count": 8,
    "column_count": 5
  },
  {
    "table_index": 5,
    "headers": [
      "Medication",
      "Dosing",
      "Metabolism (M) and Excretion (E)",
      "Mechanism of Action",
      "ALD Considerations"
    ],
    "rows": [
      [
        "Naltrexone*",
        "50 mg/d orally or 380 mg monthly sq",
        "M: Hepatic",
        "Opioid receptor antagonist",
        "Not studied in patients with ALDHepatotoxicity concerns"
      ],
      [
        "E: Mostly renal, fecal 2%‐3%"
      ],
      [
        "Acamprosate*",
        "666 mg tid",
        "M: None",
        "NMDA receptor antagonist",
        "Not studied in patients with ALDNo reported instances of hepatotoxicity"
      ],
      [
        "E: Renal"
      ],
      [
        "Gabapentin",
        "600‐1,800 mg/d",
        "M: None",
        "Modulates GABA activity through action at presynaptic calcium channels",
        "Not studied in patients with ALDMonitor closely for renal dysfunction and worsening mental status/sedation"
      ],
      [
        "E: Renal 75%, fecal 25%"
      ],
      [
        "Baclofen",
        "30‐60 mg/d",
        "M: Hepatic, limited",
        "GABA‐B receptor agonist",
        "Single RCT in patients with ALD showed benefit"
      ],
      [
        "E: Renal"
      ],
      [
        "Topiramate",
        "75‐400 mg/d",
        "M: Not extensively metabolized",
        "GABA action augmentation, glutamate antagonism",
        "Not studied in patients with ALD"
      ],
      [
        "E: Renal"
      ]
    ],
    "row_count": 10,
    "column_count": 5
  },
  {
    "table_index": 6,
    "headers": [],
    "rows": [
      [
        "Implicated in increasing the risk of alcohol‐associated liver injuryAlcohol dose above threshold of 1 drink/day (women), 2 drinks/day (men)Pattern of consumption: daily drinking; drinking while fasting, binge drinkingSmoking cigarettesWomen compared with menGenetics*:PNPLA3, TM6SF2, MBOAT7, HSD17B13Increased BMIPresence of comorbid conditions: chronic viral hepatitis, hemochromatosis, NAFLD, NASH"
      ],
      [
        "Implicated in ameliorating the risk of alcohol‐associated liver injuryCoffee consumption"
      ],
      [
        "Equivocal data regarding effect on the risk of alcohol‐associated liver injuryType of alcohol consumedModerate alcohol use in patients with high BMI"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 7,
    "headers": [],
    "rows": [
      [
        "Symptoms"
      ],
      [
        "Odor of alcohol on breath*"
      ],
      [
        "NonspecificTirednessAbdominal painDay/night reversal (sleepy by day, wakeful at night)Peripheral neuropathyWeight gain (due to ascites)Weight loss (due to loss of proximal muscle mass)Confusion (as part of hepatic encephalopathy)Loss of sexual driveAmenorrhea"
      ],
      [
        "SignsSkin: Spider angiomata, palmar erythema, leukonychia, ecchymosesEyes: Icteric conjunctivaeMusculoskeletal: Loss of proximal muscle mass, especially temporal wastingCardiovascular: Systemic hypotension; tachycardia suggests alcohol withdrawal syndrome*Abdominal: Ascites, hepatomegaly, splenomegaly, bruits, caput medusaReproductive: Gynecomastia, gonadal atrophy in menNeurological:◦Alcohol withdrawal syndrome*: Fine tremor, psychomotor agitation, transient hallucinations or illusions◦Hepatic encephalopathy: Coarse flapping tremor (asterixis), altered consciousness◦Wernicke‐Korsakoff syndromeHands: Dupuytren's contracture"
      ]
    ],
    "row_count": 4,
    "column_count": 1
  },
  {
    "table_index": 8,
    "headers": [
      "",
      "Bili",
      "PT/INR",
      "Cr/BUN",
      "Age",
      "Alb",
      "WBC",
      "Stratification",
      "Clinical Use"
    ],
    "rows": [
      [
        "MDF",
        "+",
        "+",
        "‐",
        "‐",
        "‐",
        "‐",
        "Severe: ≥32",
        "Initiate corticosteroids"
      ],
      [
        "MELD",
        "+",
        "+",
        "+",
        "‐",
        "‐",
        "‐",
        "Severe: ≥21, but a continuous scale",
        "Prognosis only"
      ],
      [
        "ABIC",
        "+",
        "+",
        "+",
        "+",
        "‐",
        "‐",
        "Low: <6.71",
        "Prognosis only"
      ],
      [
        "GAHS",
        "+",
        "+",
        "+",
        "+",
        "‐",
        "+",
        "Poor prognosis: ≥9",
        "Initiate corticosteroids if ≥9 and MDF ≥32"
      ],
      [
        "Lille",
        "+",
        "+",
        "+",
        "+",
        "+",
        "‐",
        "≥0.45: Nonresponse",
        "Day 7 cessation or continuation of corticosteroids"
      ],
      [
        "<0.45: Response"
      ]
    ],
    "row_count": 6,
    "column_count": 9
  },
  {
    "table_index": 9,
    "headers": [
      "",
      "Advantages",
      "Disadvantages"
    ],
    "rows": [
      [
        "MDF",
        "Decades of experience in AH",
        "False positives can lead to excess corticosteroid treatment"
      ],
      [
        "Key inclusion criterion in most AH trials"
      ],
      [
        "MELD",
        "Extensive experience in hepatology",
        "Uncertain threshold for initiating corticosteroids"
      ],
      [
        "ABIC",
        "Three‐tiered stratification",
        "Uncertain threshold for initiating corticosteroids and not verified outside of Spain"
      ],
      [
        "GAHS",
        "Improves specificity of patients with MDF ≥32 needing corticosteroids",
        "Not verified outside of United Kingdom"
      ],
      [
        "Lille",
        "Allows early cessation of corticosteroids",
        "Uncertain decision making with partial response (Lille 0.46‐0.56)"
      ]
    ],
    "row_count": 6,
    "column_count": 3
  }
]